Cargando…

Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study

PURPOSE: To compare 2-year treatment outcomes of ranibizumab using treat-and-extend (T&E) or pro re nata (PRN) regimens for diabetic macular edema (DME) in clinical settings. METHODS: We retrospectively enrolled 34 patients (34 eyes) with DME treated with ranibizumab using the T&E regimen, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Tso-Ting, Chen, Ta-Ching, Yang, Chang-Hao, Yang, Chung-May, Ho, Tzyy-Chang, Hsieh, Yi-Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821911/ https://www.ncbi.nlm.nih.gov/pubmed/35145975 http://dx.doi.org/10.3389/fmed.2021.781421

Ejemplares similares

Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema
por: Lai, Ivan Pochou, et al.
Publicado: (2020)

Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
por: Inoue, Maiko, et al.
Publicado: (2014)

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
por: Takamura, Yoshihiro, et al.
Publicado: (2021)

Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion
por: Unsal, Erkan, et al.
Publicado: (2015)

Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
por: Narayanan, Raja, et al.
Publicado: (2016)

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
por: Jia, Huixun, et al.
Publicado: (2022)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto, Akiko, et al.
Publicado: (2013)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
por: Elwes, Flora, et al.
Publicado: (2018)

One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
por: Wang, Fenghua, et al.
Publicado: (2019)

Real-Life Efficacy of Bevacizumab Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion according to Pro Re Nata or Treat-and-Extend Regimen in Eyes with or without Epiretinal Membrane
por: Hamam, Moustafa, et al.
Publicado: (2022)

Real-world experience with pro re nata dosing of intravitreal dexamethasone implant for eyes with refractory diabetic macular edema
por: Rishi, Pukhraj, et al.
Publicado: (2020)

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol
por: Lin, Tiezhu, et al.
Publicado: (2020)

Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial
por: Yoon, Chang Ki, et al.
Publicado: (2022)

Long-Term Change in Renal Function After Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort Study
por: Fang, Yi-Chung, et al.
Publicado: (2023)

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
por: Victor, Andi Arus, et al.
Publicado: (2022)

Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
por: Ma, I-Hsin, et al.
Publicado: (2021)

Pro Re Nata Use of Psychotropic Medications in Assisted Living
por: Carder, Paula, et al.
Publicado: (2020)

Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema
por: Tsai, Meng-Ju, et al.
Publicado: (2017)

Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema
por: Wang, Jia-Kang, et al.
Publicado: (2021)

Clinical characteristics and long-term evolution of lamellar macular hole in high myopia
por: Hsia, Yun, et al.
Publicado: (2020)

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study
por: Lai, Tso-Ting, et al.
Publicado: (2019)

Pro Re Nata Prescription and Perception Difference between Doctors and Nurses
por: Oh, Se Hwa, et al.
Publicado: (2014)

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
por: Huang, Chu-Hsuan, et al.
Publicado: (2021)

Combined quantitative and qualitative optical coherence tomography angiography biomarkers for predicting active neovascular age-related macular degeneration
por: Hsu, Cherng-Ru, et al.
Publicado: (2021)

Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review
por: Vaismoradi, Mojtaba, et al.
Publicado: (2018)

Combined intravitreal ranibizumab and posterior subtenon triamcinolone acetonide injections for patients with diabetic macular edema refractory to intravitreal ranibizumab monotherapy
por: Chiu, Chiung-Yi, et al.
Publicado: (2021)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
por: Chujo, Shinichiro, et al.
Publicado: (2020)

The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study
por: Jeng, Yu-Ting, et al.
Publicado: (2022)

Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim, Moosang, et al.
Publicado: (2013)

Critical appraisal of ranibizumab in the treatment of diabetic macular edema
por: Stewart, Michael W
Publicado: (2013)

Influence of Psychotropic Pro Re Nata Drug Use on Outcomes in Hospitalized Patients with Schizophrenia
por: Kyou, Yoshitaka, et al.
Publicado: (2023)

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016)

Full-thickness macular hole formation in proliferative diabetic retinopathy
por: Tsui, Mei-Chi, et al.
Publicado: (2021)

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration
por: Aurell, Sandra, et al.
Publicado: (2018)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

The use and effectiveness of pro re nata psychotropic medications in children and adolescents: A systematic review
por: Asogwa, Kenneth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_glbvj3r6p1u9bl4l3io6ccb0h8